SCHEMBL25545480

SCHEMBL25545480

COc1ccc(-c2nc(Cl)sc2C2CC2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.44
LMNA P02545 2/20 0.44
HPGD P15428 1/20 0.44
KDM4E B2RXH2 3/20 0.42
MAPT P10636 1/20 0.42
PTGS2 P35354 2/20 0.41
ACHE P22303 2/20 0.40
KMT2A Q03164 2/20 0.40
MAT2A P31153 1/20 0.40
MEN1 O00255 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
PKM P14618 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
PTGDR2 Q9Y5Y4 1/20 0.39
ALOX5 P09917 1/20 0.39
APP P05067 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25545454 0.84 HTR6 (0.37) ALDH1A1LMNAKDM4EMAPTNPC1
SCHEMBL25549939 0.84 ALDH1A1 (0.60) ALDH1A1LMNAHPGDKDM4EMAPT
SCHEMBL25545497 0.80 USP7 (0.35) ALDH1A1LMNAKDM4EMAPTKMT2A
SCHEMBL25545543 0.79 IGF1R (0.36) ALDH1A1LMNAKDM4EMAPT
SCHEMBL25545482 0.79 ALDH1A1 (0.43) ALDH1A1LMNAKDM4EMAPTPTGS2
SCHEMBL5530041 0.78 ALDH1A1 (0.61) ALDH1A1LMNAHPGDKDM4EMAPT
SCHEMBL25551699 0.78 BTK (0.33) LMNAMAPTNPC1RAB9ASMN1; SMN2
SCHEMBL25545483 0.77 ALDH1A1 (0.40) ALDH1A1LMNAHPGDMAPTKMT2A
SCHEMBL11751223 0.74 ALOX5 (0.58) ALDH1A1LMNAHPGDKDM4EMAPT
SCHEMBL11751772 0.74 ALOX5 (0.58) ALDH1A1LMNAHPGDKDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4392422-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. (US) 2024-07-03 EP disclosed
CN-118103368-A EIF4E inhibitors and uses thereof 皮克医疗公司 2024-05-28 CN disclosed
US-20230150997-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. 2023-05-18 US disclosed
US-20230150997-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. 2023-05-18 US disclosed
WO-2023028235-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. (US) 2023-03-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230150997-A1 EIF4E INHIBITORS AND USES THEREOF EIF4E, EIF4EBP1, EIF4A1 ALDH1A1 4776/4885LMNA 2647/4885HPGD 4535/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.